AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 208.82B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 6.99B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.48 |
| PE Ratio | 30.07 |
| Forward PE | 17.50 |
| Dividend | 2.43 (1.85%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 2,179,435 |
| Average Volume | 1,890,816 |
| Open | 13,400 |
| Previous Close | 13,126 |
| Day's Range | 13,284 - 13,508 |
| 52-Week Range | 9,574 - 13,498 |
| Beta | 0.17 |
| RSI | 75.01 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines
London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic data revealed rising unemployment and slowing wage growth, while drugmaker As...
AstraZeneca hits record high, cements lead as UK's biggest stock
Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's position as the largest UK-listed stock by market value.
Why AstraZeneca Stock Was a Winner Today
The company inches closer to bringing a new drug to a very large addressable market.
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca Plc (NASDAQ: AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as wel...
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well ...
AstraZeneca (AZN) Earns FDA Orphan Drug Status for Leukemia Treatment
AstraZeneca (AZN) Earns FDA Orphan Drug Status for Leukemia Treatment
AstraZeneca's Baxdrostat Achieves Major Breakthrough In Hypertension Treatment In Phase III Trial
(RTTNews) - AstraZeneca PLC (AZN, AZN.L) announced results from its Bax24 Phase III trial, revealing that baxdrostat significantly reduced 24-hour systolic blood pressure (SBP) in patients with treatm...
AstraZeneca (AZN) Announces Successful Phase III Trial Results for Baxdrostat
AstraZeneca (AZN) Announces Successful Phase III Trial Results for Baxdrostat
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulat...
Top global stories this week: Diageo, Novo Nordisk, AstraZeneca among notable names
AstraZeneca PLC 2025 Q3 - Results - Earnings Call Presentation
AstraZeneca (AZN) Warns UK on Drug Spending Risks
AstraZeneca (AZN) Warns UK on Drug Spending Risks
AstraZeneca (AZN) Reports Positive Phase III Trial Results for Fasenra
AstraZeneca (AZN) Reports Positive Phase III Trial Results for Fasenra
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca's FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first...
Why AstraZeneca Stock Topped the Market on Thursday
Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.
AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript
AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)
The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and EP...
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes ...
AstraZeneca PLC (AZN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances
AstraZeneca PLC (AZN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances
Q3 2025 AstraZeneca PLC Earnings Call Transcript
Q3 2025 AstraZeneca PLC Earnings Call Transcript
AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable
AstraZeneca Plc (NASDAQ: AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion , driven by d...
Britain risks losing access to the world’s best drugs, warns AstraZeneca
UK’s largest medicines group urges ministers to spend more on developing new treatments
AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar
AstraZeneca stock jumped Thursday after the drugmaker reported better-than-expected third-quarter sales and earnings.
AstraZeneca (AZN) Involved in Axsome's New Acquisition and Drug Development
AstraZeneca (AZN) Involved in Axsome's New Acquisition and Drug Development